MedTrace Logo

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

NCT02085070 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.

Conditions

Interventions

DRUG

MK-3475

IV MK-3475

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Harriet Kluger, MD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2020-02-27
Completion
2020-02-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02085070 on ClinicalTrials.gov